Aetion Company

Aetion delivers real-world evidence (RWE) and outcomes-based analytics solutions to life sciences companies, payers, and at-risk providers. With its patented rapid-cycle analytics technology, the Aetion Evidence Platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in inpatient care. Aetion is based in New York City and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, Greenspring Associates, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Amgen Ventures, Johnson & Johnson Innovation — JJDC, Inc., UCB, and Horizon Health Services, Inc.
Technology: Analytics, Health Care, Software
Industry: Data Processing, Clinical Development
Headquarters: New York, New York, United States
Founded Date: 2013-01-01
Employees Number: 101-250
Funding Status: Late Stage Venture
Investors Number: 17
Total Funding: 203600000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-05-11
Last Funding Type: Series C

Visit Website
aetionteam@finnpartners.com
https://twitter.com/aetioninc
Register and Claim Ownership